Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Downstream Versus Upstream Strategy for the Administration of P2Y12 Receptor Blockers (DUBIUS)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02618837
Recruitment Status : Recruiting
First Posted : December 1, 2015
Last Update Posted : February 18, 2019
Sponsor:
Collaborator:
Azienda Ospedaliera di Padova
Information provided by (Responsible Party):
University of Padova

Brief Summary:

To evaluate the impact on outcomes of the currently accepted antithrombotic strategies based on the administration of newer P2Y12 receptor blockers (prasugrel and ticagrelor) in a population of non ST elevated ACS (NSTEACS) patients with an initial invasive indication.

Furthermore, to evaluate the effects of bivalirudin administration in comparison to standard therapy with unfractioned heparin (plus provisional anti-GPIIbIIIa) in NSTEACSpatients who undergo PCI and will thus receive these potent antiplatelet agents which may theoretically favor the occurrence of bleedings.

A combined measure of efficacy and safety endpoints, the so-called net clinical benefit (NACE), will be considered at early (30 days) and mid term (12 months) follow-up.


Condition or disease Intervention/treatment Phase
Unstable Angina or Non ST Elevated Myocardial Infarction Procedure: Downstream strategy Procedure: Upstream strategy Phase 4

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 2520 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Diagnostic
Official Title: Downstream Versus Upstream Strategy for the Administration of P2Y12 Receptor Blockers In Non ST Elevated acUte Coronary Syndromes With Initial Invasive Indication
Actual Study Start Date : December 14, 2015
Estimated Primary Completion Date : September 2019
Estimated Study Completion Date : September 2020

Arm Intervention/treatment
Active Comparator: Downstream strategy arm
downstream administration strategy of P2Y12 receptor blockers (prasugrel or ticagrelor)
Procedure: Downstream strategy

At diagnosis:

Subjects receive a loading dose of aspirin (150-300mg). Administration of clopidogrel is allowed only for patients already receiving clopidogrel

Pre-procedure:

Until PCI is performed, all subjects will be maintained at a minimum of 75mg of aspirin (Subjects with clopidogrel may be maintained at a minimum of 75mg of clopidogrel)

Peri- and post-procedure:

For all the patients undergoing PCI, both the use of unfractioned heparin and of bivalirudin will be allowed at the time of PCI; choice based upon clinical judgement.

In this case, subject will be randomized in a 1:1 fashion to prasugrel vs ticagrelor

At the time of PCI, the loading doses required (according to randomization):

  • Ticagrelor 180mg, maintained at 90mg b.i.d. for at least 12 months
  • Prasugrel 60mg, maintained at a minimum of 75mg of aspirin for at least 12 months plus 10mg of prasugrel* daily for at least 12 months

    • If subject is >75 years old or <60 kg, daily dose of prasugrel should be 5mg

Active Comparator: Upstream strategy arm
upstream administration strategy (ticagrelor only)
Procedure: Upstream strategy

At the time of diagnosis:

Subjects randomized in this arm must receive a loading dose of aspirin (150-300 mg) and ticagrelor (180 mg) at admission as soon as possible.

Pre-procedure:

All subjects will be maintained at a minimum of 90 mg of ticagrelor b.i.d. and a minimum of 75 mg of aspirin, until coronary angiography is performed.

Peri- and post-procedure:

For all the patients undergoing PCI, both the use of unfractioned heparin and of bivalirudin will be allowed at the time of PCI; the choice of the anticoagulant at the time of PCI will be based upon clinical judgement.

All subjects randomized to the upstream strategy arm will be maintained at a minimum of 90 mg of ticagrelor b.i.d. and a minimum of 75 mg of aspirin, for at least 12 months. If the subject develops hypersensitivity or intolerance to ticagrelor, clopidogrel may be used as a substitute at a dose in accordance with standard hospital practice (to be documented in the eCRF).





Primary Outcome Measures :
  1. Incidence of NACE (Net Adverse Cardiac Events) at 30 days [ Time Frame: 30 days ]
    NACE (Net Adverse Cardiac Events) defined as a composite of: death from vascular causes (death from cardiovascular causes or cerebrovascular causes and any death without another known cause), non fatal MI, or non fatal stroke, BARC type 3, 4 and 5 bleeding.

  2. Incidence of NACE (Net Adverse Cardiac Events) at 12 months [ Time Frame: 12 months ]
    NACE (Net Adverse Cardiac Events) defined as a composite of: death from vascular causes (death from cardiovascular causes or cerebrovascular causes and any death without another known cause), non fatal MI, or non fatal stroke, BARC type 3, 4 and 5 bleeding.


Secondary Outcome Measures :
  1. Incidence of single digit and composite of death from vascular causes, MI, stroke, TIA, severe recurrent ischemia, recurrent ischemia, or other arterial thrombotic event. [ Time Frame: 30 days, 12 months ]
  2. Incidence of death from any cause [ Time Frame: 30 days, 12 months ]
  3. Incidence of any stent thrombosis according to the ARC criteria [ Time Frame: 30 days, 12 months ]
  4. Incidence of target vessel revascularization (TVR). [ Time Frame: 30 days, 12 months ]
  5. Incidence of NACE (Net Adverse Cardiac Events) occurred in the period between admission and coronary revascularization [ Time Frame: 30 days, 12 months ]
    NACE (Net Adverse Cardiac Events) occurred in the period between admission and coronary revascularization defined as a composite of: death from vascular causes (death from cardiovascular causes or cerebrovascular causes and any death without another known cause), non fatal MI, or non fatal stroke, BARC type 2, 3, 4 and 5 bleeding,

  6. Incidence of target lesion revascularization (TLR) [ Time Frame: 30 days, 12 months ]
  7. Incidence of compliance to mandated antiplatelet therapy [ Time Frame: 30 days, 12 months ]
  8. Incidence of BARC type 2, 3, 4 and 5 bleeding (single digit and composite). [ Time Frame: 30 days, 12 months ]
  9. Incidence of all TIMI major, major-life-threatening, and minor bleeding [ Time Frame: 30 days, 12 months ]
  10. Incidence of all CABG surgery-related TIMI major, minor, and composite of TIMI major or minor bleeding [ Time Frame: 30 days, 12 months ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 84 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Age ≥ 18 and < 85
  • Non ST elevated acute coronary syndrome (unstable angina, non ST elevated myocardial infarction), with an onset of symptoms during the previous 24 hours.
  • An initial invasive strategy is chosen (the patient is expected to undergo coronary angiography within 72 h from admission).
  • Subject is able to start therapy with a new P2Y12 inhibitor (prasugrel or ticagrelor) OR is on a maintenance dose of clopidogrel or ticlopidine and is able to switch to a new P2Y12 inhibitor (prasugrel or ticagrelor).
  • Subject is able to verbally confirm understanding of risks and benefits of dual antiplatelet therapy in coronary acute syndromes and he/she or his/her legally authorized representative provides written informed consent prior to any Clinical Investigation related procedure, as approved by the appropriate Ethics Committee.
  • Patient agrees to comply with follow-up evaluations.

Exclusion Criteria:

  • Known hypersensitivity/contraindication to aspirin, clopidogrel, prasugrel, ticagrelor, heparin or bivalirudin, or sensitivity to contrast media, which can't be adequately pre-medicated.
  • Platelet count <100,000 cells/mm³ or >700,000 cells/mm³, or a white blood cell (WBC) count <3,000 cells/mm³ within 7 days prior to index procedure.
  • Shock.
  • Have severe hepatic impairment defined as Child Pugh Class C.
  • Pregnant or nursing subjects and those who plan pregnancy in the period up to 3 years following screening. (Female subjects of child-bearing potential must have a negative pregnancy test done within 28 days prior to enrollment).
  • Other medical illness (e.g., cancer or congestive heart failure) or known history of substance abuse (alcohol, cocaine, heroin etc.) as per physician judgment that may cause non-compliance with the protocol or confound the data interpretation or is associated with a limited life expectancy.
  • Subject is belonging to a vulnerable population (per investigator's judgment, e.g., subordinate hospital staff or sponsor staff) or subject unable to read or write.
  • Currently participating in investigational drug or device trial that has not completed the primary endpoint or that clinically interferes with current trial endpoints. Subject must agree not to participate in any other clinical investigation for a period of three years following the index procedure, including clinical trials of medication and invasive procedures. Questionnaire-based studies, or other studies that are non-invasive and do not require medication are allowed.
  • Prior history of hemorrhagic or ischemic stroke, a transient ischemic attack (TIA), or sub-arachnoid hemorrhage.
  • History of intracranial neoplasm, arterovenous malformation, or aneurysm.
  • Have received fibrinolytic therapy within 48 hours of entry or randomization into the study.
  • Have active pathological bleeding or history of bleeding diathesis.
  • Have clinical findings, in the judgment of the investigator, associated with an increased risk of bleeding.
  • Have had recent surgery (within 4 weeks of entry into the study) or are scheduled to undergo surgery within the next 2 months.
  • Have received a loading dose of a thienopyridine (ticlopidine, clopidogrel or prasugrel) or a maintenance dose of prasugrel or Ticlopidine or Ticagrelor within 7 days of entry into the study.
  • Are receiving a GPIIb/IIIa inhibitor (eptifibatide, tirofiban, or abciximab).
  • Are receiving warfarin or other coumarin derivatives.
  • Are receiving or will receive oral anticoagulation or other oral antiplatelet therapy (except aspirin [ASA]) that cannot be safely discontinued within the next 3 months.
  • Are receiving daily treatment with nonsteroidal anti-inflammatory drugs (NSAIDs) or cyclooxygenase-2 (COX2) inhibitors that cannot be discontinued or are anticipated to require >2 weeks of daily treatment with NSAID or COX2 inhibitors during the study.
  • Concomitant therapy with a strong cytochrome P-4503A inhibitor or inducer.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02618837


Contacts
Layout table for location contacts
Contact: Gennaro De Crescenzo, Research Associate dubius.sctb.dctv@unipd.it

Locations
Layout table for location information
Italy
Azienda Ospedaliera di Padova Recruiting
Padova, Veneto, Italy, 35131
Contact: Giuseppe Tarantini, MD         
Principal Investigator: Giuseppe Tarantini, MD         
Sub-Investigator: Marco Mojoli, MD         
Sponsors and Collaborators
University of Padova
Azienda Ospedaliera di Padova

Layout table for additonal information
Responsible Party: University of Padova
ClinicalTrials.gov Identifier: NCT02618837     History of Changes
Other Study ID Numbers: DUBIUS - 0015746
First Posted: December 1, 2015    Key Record Dates
Last Update Posted: February 18, 2019
Last Verified: February 2019

Keywords provided by University of Padova:
NSTEMI
NSTEACS
prasugrel
ticagrelor
Downstream versus Upstream strategy

Additional relevant MeSH terms:
Layout table for MeSH terms
Platelet Aggregation Inhibitors
Infarction
Myocardial Infarction
Angina, Unstable
Non-ST Elevated Myocardial Infarction
Ischemia
Pathologic Processes
Necrosis
Myocardial Ischemia
Heart Diseases
Cardiovascular Diseases
Vascular Diseases
Angina Pectoris
Chest Pain
Pain
Neurologic Manifestations
Signs and Symptoms
Ticagrelor
Prasugrel Hydrochloride
Purinergic P2Y Receptor Antagonists
Purinergic P2 Receptor Antagonists
Purinergic Antagonists
Purinergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs